1023. Patients Treated with Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection Report an Improvement in Their Quality of Life
Session: Poster Abstract Session: Enteric Infection
Friday, October 9, 2015
Room: Poster Hall
Posters
  • Chaplin IDSA 2015 9-29 v1.pdf (290.2 kB)
  • Background: The diversity of colonic flora is decreased in patients with recurrent Clostridium difficile infection (CDI). Fecal Microbiota Transplantation (FMT) has been shown to be an effective treatment for recurrent CDI. The aim of this study is to assess quality of life of patients after treatment with FMT.

    Methods: We performed a retrospective chart review of outpatients treated with FMT by colonoscopy for recurrent CDI at the University of Virginia Health System from 6/2012 to 3/2015 and collected data on patient demographics, laboratory results, and patient outcomes. Per our clinic protocol, patients were closely followed with phone calls at 1 week and 3 and 6 months. Each patient is seen in clinic 1 month following FMT. For this review, we evaluated patients’ responses to questions about their overall health and quality of life, as well as specific symptoms of changes in bowel habits, abdominal pain, energy, and appetite. CDI recurrence was also examined.

    Results: Fifty patients had FMT with an average age of 67 years ± 17 SD; 80% of the cohort was female. We have 1 month follow-up on 30 patients, 3 month follow-up on 35 patients, and 6 month follow-up on 27 patients. CDI recurrence occurred in 4 patients with 1 patient recurring at 1 and 3 months. A majority reported an improvement in their overall health (n=23, 77%) at 1 month, 3 months (n=30, 86%), and 6 months (n=26, 96%). Most patients also reported improvement in their abdominal pain (n=21, 70%) at 1 month, 3 months (n=25, 71%), and 6 months (n=22, 81%). Seventy percent of patients experienced ≤3 bowel movements a day at 1 month compared to 78% at 6 months. An increase in energy level was noted by patients at 1 month (n=15, 50%) and 6 months (n=20, 74%). Thirty-seven percent reported an improved appetite at 1 month compared to 56% at 6 months.

    Conclusion: At our institution, most patients with recurrent CDI reported an improvement in quality of life after FMT, as well as normalization of their bowel habits, a decrease in abdominal pain, and an increase in energy and appetite. Our success rate for treatment of recurrent CDI is 92%, comparable to published reports. Though the cohort is small, our data suggests that patients treated with FMT experience health benefits beyond treatment of their infection.

    Ashley Chaplin, MD1, R. Ann Hays, MD2, Glynis L. Kolling, PhD1, Sheila Vance, PA2, Cirle Warren, MD1, Richard Guerrant, MD1 and Laurie Archbald-Pannone, MD, MPH1, (1)Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, (2)Division of Gastroenterology & Hepatology, University of Virginia, Charlottesville, VA

    Disclosures:

    A. Chaplin, None

    R. A. Hays, None

    G. L. Kolling, None

    S. Vance, None

    C. Warren, None

    R. Guerrant, None

    L. Archbald-Pannone, None

    See more of: Enteric Infection
    See more of: Poster Abstract Session
    << Previous Abstract | Next Abstract

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.